Literature DB >> 22312655

Investigating and managing pyrexia of unknown origin in adults.

George M Varghese1, Paul Trowbridge, Tom Doherty.   

Abstract

Few clinical problems generate such a wide differential diagnosis as pyrexia (fever) of unknown origin. The initial definition proposed by Petersdorf and Beeson in 1961,¹ later revised, is "a fever of 38.3°C (101°F) or more lasting for at least three weeks for which no cause can be identified after three days of investigation in hospital or after three or more outpatient visits." ²⁻⁴Essentially the term refers to a prolonged febrile illness without an obvious cause despite reasonable evaluation and diagnostic testing. A fever that is not self limiting for which no cause can be found can become a source of frustration for both patient and doctor. There is little consensus on how such patients should be investigated, although recent prospective studies have evaluated diagnostic protocols to suggest approaches to investigation. ³⁵⁶ We discuss evidence from epidemiological and diagnostic studies and suggest an approach to investigating and managing pyrexia of unknown origin. Immunocompromised individuals, those with HIV infection, and patients admitted to hospital for other reasons with persistent or unexplained fever represent distinct subgroups in which the likely causes, diagnosis, and treatment of pyrexia usually differ from those in patients who are not immunocompromised. We do not discuss these subgroups in this review other than to provide definitions of pyrexia of unknown origin in different groups of patients (see box 1).

Entities:  

Mesh:

Year:  2010        PMID: 22312655     DOI: 10.1136/bmj.c5470

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  9 in total

1.  Acetaminophen in critically ill patients, a therapy in search for big data analytics.

Authors:  Sven Van Poucke; Willem Boer
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

2.  Isolated aortitis: a rare cause of febrile illness.

Authors:  Alberto Fior; Paulo Barreto
Journal:  BMJ Case Rep       Date:  2015-10-01

3.  Clinical features of patients with infective endocarditis presenting to the emergency department: a retrospective case series.

Authors:  Naruhiro Jingushi; Mitsunaga Iwata; Teruhiko Terasawa
Journal:  Nagoya J Med Sci       Date:  2017-11       Impact factor: 1.131

Review 4.  Association of 18F-FDG PET or PET/CT results with spontaneous remission in classic fever of unknown origin: A systematic review and meta-analysis.

Authors:  Motoki Takeuchi; Takashi Nihashi; Anat Gafter-Gvili; Francisco Javier García-Gómez; Emmanuel Andres; Daniel Blockmans; Mitsunaga Iwata; Teruhiko Terasawa
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

5.  Safety and efficacy of outpatient follow-up for referred patients with undiagnosed fever: A retrospective cohort study.

Authors:  Yukinori Harada; Mikako Masuda; Takanobu Hirosawa; Hiroshi Takase; Kohei Morinaga; Michihiro Nin; Taro Shimizu
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

6.  Fecal Scrotal Abscess Secondary to Spontaneous Retroperitoneal Perforation of Ascending Colon.

Authors:  Akshay Bahadur; Nirmala Singh; Mayank Kashmira; Ashish Shukla; Vikas Gupta; Shashank Jain
Journal:  Case Rep Med       Date:  2021-03-29

7.  Fever of Unknown Origin: The Workup and Diagnosis of Pel-Ebstein Fever.

Authors:  Prachi Khanna; Natalie Malluru; Raaj Pyada; Mitul Gupta; Kartik Akkihal; Thomas C Varkey
Journal:  Cureus       Date:  2022-02-06

8.  Ulcerative Colitis Activity Presenting as Fever of Unknown Origin, in a Patient with Longstanding Disease under Continuous Treatment with Mesalazine.

Authors:  Panagiota Voukelatou; Elissavet Sfendouraki; Theodoros Karianos; Sofia Saranti; Dimitrios Tsitsimelis; Ioannis Vrettos; Andreas Kalliakmanis
Journal:  Case Rep Med       Date:  2016-07-18

9.  Diagnostic value of F-18 FDG PET/CT in fever or inflammation of unknown origin in a large single-center retrospective study.

Authors:  Friedrich Weitzer; Tina Nazerani Hooshmand; Birgit Pernthaler; Erich Sorantin; Reingard Maria Aigner
Journal:  Sci Rep       Date:  2022-02-03       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.